🇺🇸 FDA
Pipeline program

BI 3000202, BI 3000202, Placebo matching BI 3000202

1509-0004

Phase 2 small_molecule active

Quick answer

BI 3000202, BI 3000202, Placebo matching BI 3000202 for Systemic lupus erythematosus is a Phase 2 program (small_molecule) at Boehringer Ingelheim International GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Boehringer Ingelheim International GmbH
Indication
Systemic lupus erythematosus
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials